ZA201207482B - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity

Info

Publication number
ZA201207482B
ZA201207482B ZA2012/07482A ZA201207482A ZA201207482B ZA 201207482 B ZA201207482 B ZA 201207482B ZA 2012/07482 A ZA2012/07482 A ZA 2012/07482A ZA 201207482 A ZA201207482 A ZA 201207482A ZA 201207482 B ZA201207482 B ZA 201207482B
Authority
ZA
South Africa
Prior art keywords
inhibitors
tyrosine kinase
kinase activity
protein tyrosine
protein
Prior art date
Application number
ZA2012/07482A
Other languages
English (en)
Inventor
Stephane Raeppel
Franck Raeppel
Stephen William Claridge
Lijie Zhan
Frederic Gaudette
Michael Mannion
Norifumi Sato
Yohei Yuki
Masashi Kishida
Arkadii Vaisburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ZA201207482B publication Critical patent/ZA201207482B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2012/07482A 2010-04-16 2012-10-05 Inhibitors of protein tyrosine kinase activity ZA201207482B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
ZA201207482B true ZA201207482B (en) 2013-09-25

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2012/07482A ZA201207482B (en) 2010-04-16 2012-10-05 Inhibitors of protein tyrosine kinase activity
ZA2012/07557A ZA201207557B (en) 2010-04-16 2012-10-09 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2012/07557A ZA201207557B (en) 2010-04-16 2012-10-09 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Country Status (19)

Country Link
US (3) US8455484B2 (https=)
EP (2) EP2563794A4 (https=)
JP (2) JP2013525286A (https=)
KR (2) KR20130058006A (https=)
CN (2) CN103025740B (https=)
AR (2) AR080875A1 (https=)
AU (2) AU2011241422B2 (https=)
CA (2) CA2796054A1 (https=)
CO (2) CO6630193A2 (https=)
EA (2) EA201291052A1 (https=)
MX (2) MX2012012031A (https=)
MY (1) MY157319A (https=)
NZ (2) NZ602948A (https=)
PH (2) PH12012502070A1 (https=)
SG (2) SG184883A1 (https=)
TW (2) TW201204735A (https=)
UA (1) UA108878C2 (https=)
WO (2) WO2011127565A1 (https=)
ZA (2) ZA201207482B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
KR101257343B1 (ko) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
WO2011127567A1 (en) 2011-10-20
AU2011241420B2 (en) 2015-04-16
CO6640224A2 (es) 2013-03-22
SG184882A1 (en) 2012-11-29
AR080871A1 (es) 2012-05-16
CN102947315A (zh) 2013-02-27
WO2011127565A1 (en) 2011-10-20
MX2012012032A (es) 2012-12-17
CN103025740B (zh) 2015-07-01
UA108878C2 (ru) 2015-06-25
EP2563795A1 (en) 2013-03-06
CO6630193A2 (es) 2013-03-01
EA201291052A1 (ru) 2013-04-30
EP2563795A4 (en) 2013-10-23
AR080875A1 (es) 2012-05-16
EP2563794A4 (en) 2013-12-04
CA2796008A1 (en) 2011-10-20
NZ602954A (en) 2014-11-28
PH12012502073A1 (en) 2013-02-11
PH12012502070A1 (en) 2015-05-08
TW201204735A (en) 2012-02-01
US20110257100A1 (en) 2011-10-20
CA2796054A1 (en) 2011-10-20
MY157319A (en) 2016-05-31
CN103025740A (zh) 2013-04-03
AU2011241422A1 (en) 2012-11-01
KR20130100234A (ko) 2013-09-10
EP2563794A1 (en) 2013-03-06
TW201204734A (en) 2012-02-01
SG184883A1 (en) 2012-11-29
US20110257175A1 (en) 2011-10-20
JP2013523846A (ja) 2013-06-17
US8455484B2 (en) 2013-06-04
JP2013525286A (ja) 2013-06-20
NZ602948A (en) 2014-09-26
AU2011241422B2 (en) 2015-05-07
EA201291055A1 (ru) 2013-09-30
MX2012012031A (es) 2012-12-17
KR20130058006A (ko) 2013-06-03
US20140315801A1 (en) 2014-10-23
US8906852B2 (en) 2014-12-09
ZA201207557B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
IL288009A (en) Use of inhibitors of bruton's tyrosine kinase (btk)
IL207946A0 (en) Inhibitors of protein tyrosine kinase activity
IL221311A0 (en) Inhibitors of protein kinases
ZA201207482B (en) Inhibitors of protein tyrosine kinase activity
ZA201001512B (en) Inhibitors of protein tyrosine kinase activity
AP3210A (en) Pyrazolyt quinazoline kinase inhibitors
PL2710005T3 (pl) Inhibitory kinazy tyrozynowej
ZA201402164B (en) Protein kinase inhibitors
ZA201502783B (en) Azaquinazoline inhibitors of atypical protein kinase c
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
PH12012500712A1 (en) Inhibitors of bruton`s tyrosine kinase
ZA201309702B (en) Inhibitors of lrrk2 kinase activity
IL208719A0 (en) Inhibitors of protein kinases
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
ZA201300705B (en) Inhibitors of bruton's tyrosine kinase
PT3409278T (pt) Inibidores de proteína cinase heterocíclicos
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL232559A0 (en) Thianopyrimidines as atypical protein c kinase inhibitors
EP2665709A1 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
ZA201306855B (en) Protein kinase inhibitors
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
HU0900798D0 (en) 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
ZA201300012B (en) Synthesis and use of kinase inhibitors
GB0907120D0 (en) Inhibitors of IKK-ß serine-threonine protein kinase
GB201003949D0 (en) Inhibitors of protein kinases